An interventional study of Electronic Decision Aid and Pre-Test Genetic Counseling in Epithelial Ovarian Carcinoma and Pancreas Adenocarcinoma, sponsored by Massachusetts General Hospital. Completed at 2 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-02.
Sponsored by Massachusetts General Hospital · Not applicable, Interventional, and Health services research
This is a randomized trial to evaluate the effectiveness of an electronic decision aid tool versus a traditional genetic counselor session for multi-gene panel testing for people with ovarian or pancreatic cancer
The research study procedures include: screening for eligibility and study questionnaires that would be performed in conjunction with either the genetic counselor visit or use of the electronic decision aid. The study questionnaires include:
The research study will last up to 2 weeks. It is expected that about 350 people will take part in this research study.
The National Cancer Institute (NCI) is supporting this research study by providing funding for the research
1,617 studies on the registry are indexed under Carcinoma, Ovarian Epithelial; 246 are open to participants now.
This study's enrollment of 297 is above the median of 47 across 1,194 interventional studies indexed under Carcinoma, Ovarian Epithelial.
Browse Carcinoma, Ovarian Epithelial studies →Massachusetts General Hospital is the lead sponsor of 2,536 studies on the registry; 446 are open to participants now.
Of its 214 completed or terminated interventional studies of FDA-regulated products, 161 (75%) have results posted.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria :
Receive decision aid followed by an appointment with their oncologist.
Behavioral: Electronic Decision Aid
Receive pretest counseling with a genetic counselor.
Behavioral: Pre-Test Genetic Counseling
Decision aid followed by an appointment with an oncologist. Will complete surveys/questionnaires
Receive pretest counseling with a genetic counselor. Will complete surveys/questionnaires
Decisional Conflict Scores
The decisional conflict score is a score ranging from 0-100 that is measured from a 10-question validated decisional conflict scale. The scale assesses participant's confidence in their decision with higher scores indicating higher decisional conflict.
Time frame: 1 week after genetics session
Average change in knowledge survey score
Average change in score on a 10-question knowledge survey to assess basic information about genetics and genetic testing that was covered in their appointment. Scores on the scale range from 0-10. Higher values in the change in knowledge survey score suggest greater amount of knowledge gained in the genetics session.
Time frame: baseline (prior to participant completing either genetics sessions) to 1-week following session, approximately 2 weeks
Shared Decision Making Process Scores
The shared decision making process score is a score on a scale of 1-4 based on responses on a validated 4-item shared-decision making scale. The scale assesses how well the decision aid/oncology provider, or the genetic counselor engaged in shared decision-making as perceived by the subject. Higher scores on this scale indicate more shared decision making.
Time frame: 1 week after genetics session
Average time between genetic testing recommendation and sample collection
Difference between the two study arms in the time it takes between participants being recommended for genetic testing and a sample being collected.
Time frame: Initial recorded recommendation/referral for genetic testing until the date of sample collection, assessed up to 6 months
Average Duration of Decision Making Process
Amount of time patients spend learning and making a decision about genetic testing in both arms of the study.
Time frame: Approximately 30 minutes - 1 hour
Ratio of the number of participants who chose each of the three panels offered
Ratios of participants who choose the small, intermediate, and broad testing panel in both arms of the study.
Time frame: At the conclusion of genetics session (day 1)
Percentage of participants choosing genetic testing
Percentage of participants in each arm of the study who choose to get genetic testing after the educational intervention
Time frame: At the conclusion of genetics session (day 1)
Documents are hosted by the registry — open the source record to download them.
Plan to share: Yes — The Dana-Farber / Harvard Cancer Center encourages and supports the responsible and ethical sharing of data from clinical trials. De-identified participant data from the final research dataset used in the published manuscript may only be shared under the terms of a Data Use Agreement. Requests may be directed to Sponsor Investigator or designee. The protocol and statistical analysis plan will be made available on Clinicaltrials.gov only as required by federal regulation or as a condition of awards and agreements supporting the research.
Supporting information: Study protocol, Sap
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Carcinoma, Ovarian Epithelial→
Massachusetts General Hospital